Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon's Pharmacology Research

2020-04-25
|
Page View:

Medicilon’s Technology Department aims to meet customers’ one-stop service needs for API R&D, utilize rich medicinal chemistry experience to efficiently promote customers’ drug R&D projects, promote new drug processes into new drug clinical research earlier, and effectively help customers Control the cost of new drug development.

The process department currently has a total area of about 6000 square meters, including a 2000 square meters research and development laboratory, 800 square meters non-GMP pilot scale-up workshop, 1000 square meters GMP API workshop and 1000 square meters analysis and testing center, 800 square meters of GMP-compliant QC laboratory, 200 square meters of microorganisms laboratory. The experimental equipment is complete and the technology is advanced. The main equipment includes different types of glass reactors, rotary evaporators, stainless steel reactors, vacuum drying ovens, blast ovens, temperature control units, precision filters, two-in-one filters, and centrifugals. Machine, jet mill, turbo mill, etc. The main analytical instruments include UPLC, HPLC, GC, IC, LC-MS, GC-MS and other chromatographic analyzers, as well as laser particle size analyzer (PSD), constant temperature and humidity test chamber, differential scanning calorimeter (DSC), Thermogravimetric analyzer (TGA), X-ray powder diffraction (XRPD), nuclear magnetic resonance (NMR), Fourier transform infrared spectroscopy (FT-IR), ultraviolet spectrophotometer, polarimeter, muffle furnace, melting point meter, moisture Tester (KF), conductivity meter, TOC and ICP-MS, etc.

Fourier transform infrared spectroscopy

Laboratory equipment of Medicilon

After years of accumulated experience and laboratory construction, Medicilon’s Process Department can not only carry out the research and development, inspection and stability of generic drugs for customers, but also carry out the research and development, production, inspection and stability of clinical phase I and phase II innovative drugs. Sexual research has gradually developed from process research and development to industrial commercial production, and from CRO to CDMO.

Gorgeous transformation, from CRO to CDMO

From the pre-clinical small-scale synthesis, process development to commercial production stage, Medicilon’s Technology Department deeply connects with the entire supply chain system of the company’s R&D, procurement, and production, and provides companies with innovative process development and large-scale production services.
Medicilon has established a GMP-compliant API workshop, and at the same time improved the level of drug production and quality management systems, can provide customers with customized services for GMP production, help more research and development enterprises carry out actual technology transformation, and shorten the time to market. Promote commercialization.

Excellent soldiers, only for high-quality and high-yield craftsmanship
We have a strong R&D team to support API process R&D services, covering areas including synthesis, analysis, microbiology, project management and QA, QC, etc.
Through continuous investment in laboratory equipment and the establishment of GMP workshops, we are committed to providing customers with high-quality products and services through prolific, fast, problem-solving and active communication, and realize the transition from CRO to CDMO, and expand the scope of pharmaceutical services business capabilities , And at the same time improve the ability and level of pharmacy services.

    Medicilon’s CDMO Service Platform

Medicilon has constructed the GMP Drug Products Pilot Plant to meet the rising needs for innovative medicine R&D, production, packaging, inspections and stability tests. We are aiming for qualified CDMO services for clients with requirements for the development of innovative medicine.

About Medicilon

Medicilon (stock code: 688202) is a drug development outsourcing service company (CRO). Founded on February 2, 2004, the company has gone through 16 years and established a company in Shanghai that integrates compound synthesis, compound activity screening, structural biology, pharmacodynamic evaluation, pharmacokinetic evaluation, toxicology evaluation, and formulation research A comprehensive technical service platform that conforms to international standards and is integrated with new drug registration, and has been recognized by the international drug administration. Medicipua’s animal laboratory facilities have obtained AAALAC (International Association for Animal Evaluation and Certification) certification and National Medical Products Administration NMPA GLP certification, and have reached the US Food and Drug Administration GLP standard.

Medicilon has a wealth of experience in global cooperation. Since 2015, Medicilon has served more than 500 active customers worldwide. It has served many global pharmaceutical companies such as Takeda Pharmaceuticals, Johnson & Johnson Pharmaceuticals, GlaxoSmithKline, Roche Pharmaceuticals, etc. R&D outsourcing services are provided by well-known domestic and foreign customers such as Swiss Medicine, Yangzijiang Pharmaceutical, CSPC, Huahai Pharmaceutical, and Zhongsheng Pharmaceutical.

contact us
Email: marketing@medicilon.com
Tel: +86 (21) 5859-1500

Return
Relevant newsRelevant news